ACOG supports the CDC recommendation for ABRYSVO4
ABRYSVO: the only maternal RSV vaccine recommended by the CDC for immunization of pregnant people at 32 weeks and 0 days’ through 36 weeks and 6 days’ gestation from September to January in most regions.1-3
In jurisdictions with RSV seasonality that differs (Alaska, southern Florida, Guam, Hawaii, Puerto Rico, US-affiliated Pacific Islands, and US Virgin Islands), providers should follow state, local, or territorial guidance on timing of ABRYSVO.
ACOG supports the CDC recommendation for ABRYSVO4
For eligible patients, this tool estimates the ABRYSVO vaccination window based upon estimated pregnancy due date, season, and location, consistent with the approved ABRYSVO indication and CDC recommendation.
Learn about RSV, a common virus that’s particularly dangerous for infants.7
Learn about Pfizer’s needle-free reconstitution options.‡
Learn more about coverage for this RSV vaccine for eligible pregnant patients.
Discover helpful ABRYSVO resources and patient materials.
Mon-Fri, 9 am – 5 pm ET
Mon-Fri, 9 am – 5 pm ET
Mon-Fri, 9 am – 5 pm ET
References: